Opendata, web and dolomites

PROSKit SIGNED

Prostate cancer urinary diagnostic kit based on RNA biomarkers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROSKit project word cloud

Explore the words cloud of the PROSKit project. It provides you a very rough idea of what is the project "PROSKit" about.

accurate    dna    capability    proprietary    preparation    simultaneously    stabilization    home    proposing    clinical    room    unnecessary    28    biotechnology    certify    60    biomarker    competitors    point    14    mix    requiring    perform    chemicals    lt    arcis    rna    nucleic    molecular    environment    specificity    acids    invasively    validation    laboratory    85    respect    psa    inexpensive    sampling    device    price    business    stability    anywhere    patients    license    poc    biopsy    holdings    segment    tested    preserving    assay    market    protocol    samples    patient    gt    2025    weeks    minutes    billion    collect    thousands    offers    11    informative    hours    false    throughput    prostate    diagnosis    care    days    extend    tools    biomarkers    surgery    pca3    specialized    positive    proskit    blood    intact    lab    ready    reduce    cancer    validate    amplifiable    platform    patented    kits    location    stabilise    diagnostic    central    sensitivity    analysed    10    temperature    biopsies    validated    tests    unstable    rapid    discriminative    core    urine    revenues    collected    collection   

Project "PROSKit" data sheet

The following table provides information about the project.

Coordinator
ARCIS BIOTECHNOLOGY HOLDINGS LIMITED 

Organization address
address: SUITE F42, THE INNOVATION CENTRE KECKWICK LANE
city: DARESBURY WARRINGTON
postcode: WA4 4FS
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARCIS BIOTECHNOLOGY HOLDINGS LIMITED UK (DARESBURY WARRINGTON) coordinator 50˙000.00

Map

 Project objective

Arcis Biotechnology Holdings developed and patented PROSKit, a molecular diagnostic platform for the diagnosis of prostate cancer based on urine analysis, able to reduce the number of false positive from the PSA test and so the number of unnecessary biopsies. PROSKit is a proprietary mix of chemicals, that can stabilise nucleic acids (RNA/DNA) in urine for up to 2 weeks at room temperature and then allow sampling at home or Point of Care (PoC) using a patient-friendly sample collection technology, preserving unstable RNA biomarkers and analysis in specialized clinical environment through the PCA3 biomarker. With respect to current diagnostic methods (PSA biopsy), PROSKit offers i) Rapid- samples ready for analysis in <3 minutes, results in <2 hours if tested at surgery, compared to days for biopsy, ii) Accurate- greater sensitivity and specificity than current PSA blood test: PCA3 presents a 28% higher discriminative capability than PSA; iii) Inexpensive- as informative as multi-core biopsy for <10% of the price; iv) High throughput- PROSKit samples can be collected anywhere, non-invasively and thousands analysed simultaneously at a central location. Compared to competitors proposing RNA stabilization requiring laboratory analyses, complex procedures and specific tools, PROSKit offers stabilization at room temperature and with no lab equipment in 3 minutes. Intact amplifiable RNA biomarkers have already been validated for 7 days stability but needs to extend validation for >14 days, validate the protocol for patients to collect urine and analysts to perform assay; certify design of PROSKit device and cost for the device and define agreement with partners for distribution and license for execution of tests. DNA/RNA Sample preparation business market revenues are expected to reach 1.85 billion € in 2025. Kits segment represents 60% of the market: 1.11 billion € in 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROSKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROSKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More